COMMONWEALTH EQUITY SERVICES, LLC - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 117 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.

Quarter-by-quarter ownership
COMMONWEALTH EQUITY SERVICES, LLC ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$1,148
+0.6%
162,0840.0%0.00%0.0%
Q2 2023$1,141
-14.8%
162,084
+0.9%
0.00%
-33.3%
Q1 2023$1,339
-24.6%
160,599
+3.8%
0.00%
-25.0%
Q4 2022$1,775
-99.9%
154,699
-7.7%
0.00%
-20.0%
Q3 2022$2,110,000
+19.2%
167,530
+0.1%
0.01%0.0%
Q2 2022$1,770,000
-37.2%
167,360
-3.4%
0.01%
-16.7%
Q1 2022$2,817,000
+19.1%
173,292
+1.5%
0.01%
+20.0%
Q4 2021$2,365,000
+36.9%
170,807
+42.1%
0.01%
+25.0%
Q3 2021$1,727,000
-9.5%
120,223
-0.5%
0.00%
-20.0%
Q2 2021$1,909,000
+52.1%
120,799
-2.2%
0.01%
+25.0%
Q1 2021$1,255,000
+42.3%
123,459
+4.2%
0.00%
+33.3%
Q4 2020$882,000
+114.6%
118,455
-1.2%
0.00%
+200.0%
Q3 2020$411,000
-23.3%
119,896
+6.6%
0.00%
-50.0%
Q2 2020$536,000
+169.3%
112,496
+12.9%
0.00%
+100.0%
Q1 2020$199,000
-31.8%
99,612
+17.6%
0.00%0.0%
Q4 2019$292,000
+77.0%
84,680
+46.7%
0.00%0.0%
Q3 2019$165,000
-17.9%
57,730
+8.5%
0.00%0.0%
Q2 2019$201,000
-42.9%
53,230
+22.8%
0.00%
-50.0%
Q1 2019$352,000
+0.9%
43,3300.0%0.00%0.0%
Q4 2018$349,000
+5.8%
43,3300.0%0.00%0.0%
Q3 2018$330,000
+33.1%
43,3300.0%0.00%
+100.0%
Q2 2018$248,000
+19.8%
43,330
-0.5%
0.00%0.0%
Q1 2018$207,000
-1.9%
43,530
+1.4%
0.00%0.0%
Q4 2017$211,00042,9300.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q4 2017
NameSharesValueWeighting ↓
VHCP Management II, LLC 6,071,142$38,430,00018.43%
RTW INVESTMENTS, LP 4,078,895$25,819,0009.72%
VHCP Management, LLC 1,155,104$7,312,0007.86%
RA Capital Management 2,989,795$18,925,0002.68%
DLD Asset Management, LP 1,258,700$7,967,0002.61%
Avoro Capital Advisors LLC 1,631,502$10,327,0002.09%
Ghost Tree Capital, LLC 1,150,000$7,280,0001.75%
GREAT POINT PARTNERS LLC 725,000$4,589,0000.94%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,237,734$20,495,0000.84%
Baker Brothers Advisors 10,963,944$69,402,0000.68%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders